Zenagamtide
amycretin · NNC0487-0111 · Novo Nordisk
One molecule activates both GLP-1 and amylin receptors.
Selected study results
Amycretin · dose escalation, Part BMean body-weight reductionBody weight decreased 24.3% · 36 weeks · Phase 1b/2a
Mean body-weight reduction · 36 weeks
Study focus: Weight management without type 2 diabetes
Adults with overweight or obesity without diabetes; N is across all five trial parts · Subcutaneous escalation to 60 mg weekly vs placebo · Trial N=125 · Estimated mean change; published dose-escalation analysis. Results & methods ↗
Small early-phase cohorts and an escalation design. The result is not Phase 3 evidence or a result for the oral formulation.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
Oral zenagamtide · Phase 2 type 2 diabetesHbA1c change · primary endpointHbA1c decreased 1.4 percentage points · 36 weeks · Phase 2
HbA1c change · primary endpoint · 36 weeks
Study focus: Glycemic control in type 2 diabetes
HbA1c fell 1.4 percentage points at 50 mg; the estimated difference from placebo was 1.09 points.
Adults with type 2 diabetes receiving metformin, with or without an SGLT2 inhibitor · 50 mg once daily; placebo-controlled dose-finding study · Trial N=186 · Efficacy estimand; on-treatment data without rescue medication. Results & methods ↗ · Publication ↗
This is a diabetes trial, not an obesity weight-loss trial. The chart shows the active arm only; the abstract reports the placebo-adjusted difference rather than a separate placebo-arm mean.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Phase 3 includes separate obesity, type 2 diabetes, sleep-apnea, knee-osteoarthritis, heart-failure, and maintenance studies.
Next: Results from the separate oral and injectable AMAZE programs, including weight management and obesity-related conditions.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies8 records
AMAZE 1
Weight managementAdults with obesity or overweight; injectable zenagamtide versus placebo.
AMAZE 12
Weight maintenanceWeight-loss maintenance in adults with obesity who reach target dose during a run-in period.
AMAZE 2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; weight-management outcomes.
AMAZE 5
Weight management with knee osteoarthritisAdults with overweight or obesity and knee osteoarthritis; evaluates weight and pain outcomes.
AMAZE 6
Weight management with knee osteoarthritisAdults with overweight or obesity and knee osteoarthritis; separate study from AMAZE 5.
AMAZE 7
Comparative weight managementSeparate registered zenagamtide protocol. Registry recruiting; outcomes pending.
AMAZE 8
Comparative weight management with type 2 diabetesPhase 3 comparison of zenagamtide with semaglutide in adults with overweight or obesity and type 2 diabetes. Registry lists 985 actual participants, actual start May 20, 2026 and primary relative body-weight change at week 84. Active, not recruiting per November 10 update; no results are posted.
AMAZE 9 · oral program
Weight management · oral formulationRegistered separate oral zenagamtide Phase 3 obesity study; no results posted.
Phase 1 studies1 record
Amycretin Phase 1b/2a · dose escalation, Part B
Weight management without type 2 diabetesPublished early dose-escalation study; the displayed 36-week Part B result is for subcutaneous treatment, not tablets.
Related conditions and outcomes
Phase 3 studies5 records
AMAZE 3
Sleep-apnea outcomesAdults with overweight or obesity and obstructive sleep apnea who are not treated with positive-airway-pressure therapy.
AMAZE 4
Sleep-apnea outcomesAdults with overweight or obesity and obstructive sleep apnea treated with positive-airway-pressure therapy.
AMBIENCE
Cardiovascular outcomesSeparate registered zenagamtide protocol. Registry is not yet recruiting despite sponsor-reported program initiation; outcomes pending.
AMBITION 7
Glycemic control in type 2 diabetesSeparate registered zenagamtide protocol. Registry recruiting; outcomes pending.
HF-POLARIS
Heart-failure outcomesMorbidity and mortality in adults with obesity and HFpEF or HFmrEF.
Phase 2 studies1 record
Oral zenagamtide Phase 2 diabetes study
Glycemic control in type 2 diabetes36-week randomized, placebo-controlled oral dose-finding study; primary endpoint HbA1c. This protocol also includes a separate injectable study.
